FY2027 Earnings Estimate for Omeros Issued By HC Wainwright

Omeros Corporation (NASDAQ:OMER - Free Report) - Stock analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Omeros in a note issued to investors on Monday, July 14th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will post earnings per share of ($0.97) for the year. HC Wainwright currently has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros' FY2028 earnings at ($0.19) EPS and FY2029 earnings at $0.98 EPS.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Friday, May 16th. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Monday, June 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Performance

OMER traded down $0.12 on Tuesday, hitting $3.37. 548,311 shares of the company were exchanged, compared to its average volume of 744,424. The firm has a fifty day simple moving average of $3.44 and a two-hundred day simple moving average of $6.59. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60. The stock has a market capitalization of $197.16 million, a PE ratio of -1.27 and a beta of 2.16.

Institutional Investors Weigh In On Omeros

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its position in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Omeros in the 4th quarter worth approximately $46,000. Picton Mahoney Asset Management grew its position in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 4,404 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares during the last quarter. Finally, Harbour Investments Inc. grew its position in shares of Omeros by 51.9% in the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 3,149 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.